Format

Send to

Choose Destination
Otolaryngol Head Neck Surg. 2008 Sep;139(3):414-20. doi: 10.1016/j.otohns.2008.06.003.

Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux.

Author information

1
Department of Otorhinolaryngology-Head and Neck Surgery, Ludwig Maximilians University, Munich, Germany. Oliver.Reichel@med.uni-muenchen.de

Abstract

OBJECTIVE:

To determine the efficacy of proton pump inhibitor (PPI) therapy with esomeprazole on symptoms and signs associated with laryngopharyngeal reflux (LPR).

STUDY DESIGN AND METHODS:

Prospective, double-blind, randomized, placebo-controlled study. Sixty-two patients with a reflux finding score (RFS)>7 and a reflux symptom index (RSI)>13 were enrolled and received either esomeprazole 20 mg twice daily or placebo for three months. RSI and RFS were assessed at baseline, after six weeks, and after three months.

RESULTS:

Reductions of total RSI and RFS as well as of several subscores were significantly higher in the treatment group compared to placebo after three months (P<0.05 each). The difference between study groups was most pronounced for posterior commissure hypertrophy (P<0.01).

CONCLUSION:

In the treatment of LPR-related symptoms a high placebo effect can be observed. However, compared to control, twice-daily PPI treatment for three months demonstrated a significantly greater improvement in laryngeal appearance and LPR symptoms.

Comment in

PMID:
18722223
DOI:
10.1016/j.otohns.2008.06.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center